Roswell Park Comprehensive Cancer Center has formed an academic cooperation with the Jagiellonian University in Kraków.
The collaboration will see the two centers exchanging staff, students and scientific resources to undertake basic, translational and clinical research in order to advance the development of cancer therapies.
The agreement grew out of a July 2018 visit by Polish Secretary of State Anna Maria Anders to Roswell Park. Four Roswell Park faculty leaders, joined by Anders, recently traveled to Kraków to initiate the collaboration: Kunle Odunsi, deputy director, chair of gynecologic oncology and executive director of the Center for Immunotherapy; Pawel Kalinski, vice chair for translational research and Rustum Family Professor for Molecular Therapeutics and Translational Research; Agnieszka Witkiewicz, director of the Center for Personalized Medicine and chief for research in the Department of Pathology; and Danuta Kozbor, associate professor of immunology and microbiology.
The agreement is effective immediately, and could see exchange of students and faculty between the two centers as early as spring 2019.
Roswell Park partners with Jagiellonian University in Kraków
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
YOU MAY BE INTERESTED IN
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.


Rick Pazdur’s appointment as director of the FDA’s Center for Drug Evaluation and Research (CDER) comes at exactly the right moment, both for the agency and for the patients it serves.


Top FDA officials said the agency is in the process of removing the black box safety warnings from all forms of menopausal hormone therapy, including creams, pills, and other treatments prescribed to ease the symptoms of menopause and perimenopause.


With the recent FDA approval of daratumumab for high-risk smoldering multiple myeloma, the moment is ripe to revisit the evolution of our understanding of smoldering multiple myeloma. This development not only underscores the growing recognition of early intervention but also invites a broader reflection on the biological insights and therapeutic strategies that have shaped—and continue to shape—this transitional disease state.


The landscape of cancer treatment is rapidly evolving. Increasingly, there is recognition that care must go beyond treating the disease itself—it must also address the whole person and the debilitating symptoms patients experience during and after treatment.





